Recordati S.p.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Koremans
- Full Time Employees
- 4,693
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Via Matteo Civitali,1 Milan MI Italy 20148
- IPO Date
- Dec 17, 2010
- Website
- recordati.com
- Similar Companies
- Business
- Recordati Industria Chimica e Farmaceutica S.p.A. researches, develops, manufactures and markets pharmaceuticals worldwide, operating through Specialty and Primary Care, and Rare Diseases segments. The company offers a broad portfolio of proprietary and licensed products across therapeutic areas including cardiovascular disorders such as hypertension, angina pectoris and cardiac rhythm disorders with flagship brands Zanidip (lercanidipine, a calcium-channel blocker), Avodart/Combodart/Duodart (dutasteride) and Vazkepa (icosapent ethyl); urogenital treatments for benign prostatic hyperplasia and lower urinary tract symptoms; central nervous system therapies including Reaglia for schizophrenia; anti-infectives such as antibiotics, antivirals, Lomexin for gynecological and dermatological infections and Hexaspray throat spray; gastroenterology products; pain management; dermatologicals; obstetrics and gynecology; over-the-counter pharmaceuticals; consumer healthcare and dietary supplements via Natural Point srl including Magnesio Supremo; and rare disease treatments such as Isturisa (pasireotide) for Cushing's syndrome, Cystadrops for cystinosis, Eligard for hormone-dependent prostate cancer, Sylvant for oncology indications, and pipeline candidates REC 0559 for neurotrophic keratitis and REC 0545 for maple syrup urine disease. Founded in 1926 as Laboratorio Farmacologico Reggiano by Giovanni Recordati in Correggio, Italy, and headquartered in Milan following the 1953 headquarters transfer, the company employs around 4,580 people and maintains operations in approximately 150 countries across Europe, Russia, CIS countries, Ukraine, Turkey, North Africa, US, Canada, Mexico, South America, Japan, Australia and other regions through subsidiaries including Recordati Rare Diseases, Casen Recordati, Jaba Recordati, Recordati Ilaç, Opalia Recordati, Italchimici, Recordati AG and others. Recent developments include the October 2024 agreement with Sanofi to acquire global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease, for an upfront US$825 million plus up to US$250 million in milestones, expected to close by year-end and immediately accretive to EBITDA; a license and supply agreement with Amarin to commercialize Vazkepa strengthening its cardiovascular franchise; ongoing expansion of its rare diseases portfolio into endocrinology and oncology; and prior acquisitions such as EUSA Pharma, Tonipharm, Natural Point, Pro Farma AG and Italchimici to bolster specialty, primary care and OTC offerings.
Company News
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q1 2026 Earnings Call Transcript
Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q4 2025 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P.
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q3 2025 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2024 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q2 2023 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q1 2023 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q4 2022 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2022 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q2 2022 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q1 2022 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q4 2021 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q3 2021 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q2 2021 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q1 2021 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q4 2020 Results - Earnings Call Transcript
5 High-Quality Stocks in the Mediterranean